NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Guardant Health, Inc. (GH) Stock Analysis

Guardant Health, Inc. (GH) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

GH

$161.41

+$0.37 (+0.23%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GH with… →

GH Key Statistics

As of Sep 4, 2026
Trading
Open
$160.00
Previous Close
$161.04
Day's Range
154.00–164.84
52-Week Range
53.40–176.58
Volume
2.40M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.58
Valuation
Market Cap
$21.66B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.31
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.51
Financials (FY)
Revenue (FY)
$982.02M+32.88%
Net Income (FY)
−$416.28M
Profit marginThe share of revenue left as profit after all costs and taxes.
−38.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
134.20M
1-Year Return
+163.05%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
2.53M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+58.03%
2025+234.34%
2024+12.94%
2023−0.55%
2022−72.81%
2021−22.39%
2020+64.93%
2019+107.87%
2018 (partial year)+16.74%

As of September 4, 2026.

GH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$982.02M−$416.28M−42.4%
2024$739.02M−$436.37M−59.0%
2023$563.95M−$479.45M−85.0%
2022$449.54M−$654.59M−145.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$982.02M$633.01M−$437.25M−$416.28M−42.4%
2024$739.02M$449.22M−$443.59M−$436.37M−59.0%
2023$563.95M$336.90M−$564.73M−$479.45M−85.0%
2022$449.54M$293.21M−$544.38M−$654.59M−145.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GH Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricGHDiagnostics & Research medianvs median
P/S ratio18.314.993.7x the median
Profit margin−38.33%0.00%38.3 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Guardant Health, Inc. (GH) at $21.66B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 2,490 employees.

The most recent close on file for GH is $161.41, dated September 4, 2026. That is +$0.37 (+0.23%) against the previous close. The 52-week range on file runs from $53.40 to $176.58. The latest close sits 202.27% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $982.02M. That is +32.88% against the prior fiscal year, when revenue was $739.02M. The same year closed with a net loss of $416.28M. Profit margin runs at −38.33%. That is 38.3 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −3.51.

Across the 4 fiscal years on file, revenue moves from $449.54M in 2022 to $982.02M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 18.31. On price-to-sales that is 3.7 times the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 1.58. Daily returns over the trailing 7 years annualize to a volatility of 64.54%. The trailing one-year price return is +163.05%. Measured over 5 years, that is +4.15% a year compounded.

Growth & Income

No dividend is on file for GH.

The strongest complete calendar year on file is 2025 at +234.34%; the weakest is 2022 at −72.81%. Of the 7 complete calendar years on file, 4 finished higher. 2026 is still running; the price is +58.03% year to date.

Peer Comparison

Guardant Health, Inc. (GH) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Guardant Health, Inc. GH $21.66B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Guardant Health, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Visit website →